41467-01-0

Basic information

• Product Name: 1-methylpiperidine-2-carbaldehyde
• Synonyms: 1-methylpiperidine-2-carbaldehyde;1-methyl-2-Piperidinecarboxaldehyde
• CAS NO: 41467-01-0
• Molecular Formula: C₇H₁₃NO
• Molecular Weight: 127.18422
• Mol File: 41467-01-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-methylpiperidine-2-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 1-methylpiperidine-2-carbaldehyde(41467-01-0)
• EPA Substance Registry System: 1-methylpiperidine-2-carbaldehyde(41467-01-0)

Safety Data

• Hazardous Substances Data: 41467-01-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-methylpiperidine-2-carbaldehyde is used as a reagent for the synthesis of phenylpyridone derivatives. These derivatives have demonstrated potential as anti-obesity agents in mice, making them a valuable contribution to the development of treatments for obesity and related metabolic disorders.
In the synthesis process, 1-methylpiperidine-2-carbaldehyde acts as a building block, providing the necessary structural framework for the formation of phenylpyridone compounds. The aldehyde group in the compound can undergo various chemical reactions, such as reduction, oxidation, or condensation, to form the desired phenylpyridone derivatives with potential anti-obesity properties.
The use of 1-methylpiperidine-2-carbaldehyde in the pharmaceutical industry highlights its importance as a versatile and valuable chemical intermediate. Its role in the synthesis of compounds with potential therapeutic applications underscores the significance of this compound in the ongoing efforts to develop new and effective treatments for obesity and related health issues.

Upstream product

• 112391-00-1 2-(1,3-dioxolan-2-yl)-1-methylpiperidine 
• 20845-34-5 (1-methyl-piperidin-2-yl)-methanol 
• 1121-60-4 pyridine-2-carbaldehyde 
• 5693-54-9 2-(1,3-dioxolan-2-yl)pyridine 
• 112390-98-4 2-(1,3-dioxolan-2-yl)-1-methylpyridinium iodide 

Downstream Products

• 1130154-42-5 N-(3-chloro-4-fluorophenyl)-7-[(2E)-3-(1-methylpiperidin-2-yl)prop-2-enoyl]-5,6,7,8-tetrahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidin-4-amine 
• 1269662-74-9 (E)-N-[4-[[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-3-(1-methyl-2-piperidinyl)prop-2-enoylamine 

Relevant articles and documents

COMPOUNDS AND USE FOR TREATING CANCER

The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

The present disclosure relates to 6-amino quinazoline or 3-cyano quinoline derivatives, preparation processes and pharmaceutical compositions containing them. Specifically, the present disclosure relates to novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by formula (I), or its tautomer, enantiomer, diastereomer, racemate or pharmaceutically acceptable salts thereof, or metabolite, metabolic precursor or prodrug thereof, and the uses for treatment especially for protein kinase inhibitors, in which each substitute group of general formula (I) is as defined in the specification.

6-AMINO QUINAZOLINE OR 3-CYANO QUINOLINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF

6-amino quinazoline or 3-cyano quinoline derivatives, preparation methods and pharmaceutical uses thereof are disclosed. Specifically, the present disclosure discloses novel 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, and their uses as treatment agents especially as protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification.

SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF

This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.

Rigidified acetylcholine mimics: Conformational requirements for binding to neuronal nicotinic receptors

Rigidified derivatives have been designed and synthesized assuming the g+t conformer of acetylcholine (N-C-C-O=+60°, C-C-O-C=180°) as active conformation for binding to cytisine sensitive neuronal nicotinic receptors. The SAR of the compounds evaluated, along with those of more flexible analogues, support the g+t conformer hypothesis and highlight the stringent steric limitation of this nicotinic receptor sub-type. Compound 3e has low μM affinity for cytisine sensitive nicotinic receptor binding sites while being selective with regard to the α-bungarotoxin sensitive subclass. We also report few compounds with μM affinity for the α-bungarotoxin sensitive subclass.

Synthesis of 1'-Methylspiro from 1-Methyl-n-piperidinecarbaldehydes

1'-Methylspiro 2 can be obtained from 1-methyl-n-piperidinecarbaldehydes 1 by the Fischer reaction of their phenylhydrazones.The Fischer reaction provides different kinds of products -3H-indole, indole and oxindole- which depend on the N atom position in the piperidine ring.